- Change Language
- Home
- Overview
- Subscribers
- Locations
- Newsroom
Following the decision by the Danish Health Authority to pause COVID-19 vaccination campaign with the Oxford/AstraZeneca vaccine, the European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee PRAC states that the benefits of the vaccine outweighs its risks. The number of thromboembolic events reported in vaccinated people is not much higher than reported in the general population, and so "the vaccine can continue to be administered while investigation of cases of thromboembolic events is ongoing." The EMA will continue to provide updates as the assessment progresses.
Pandemic Information Webinars
(Available to Pandemic Subscribers only)
Register for upcoming events
View/Download previous webinars
Additional data provided by
English
Japanese
